Zydus Lifesciences Limited has informed the Exchange about General Updates
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences, through its subsidiary Zydus Worldwide DMCC, has signed a definitive agreement to acquire all outstanding shares of U.S.-based Assertio Holdings, Inc. for USD 23.50 per share in cash, representing total consideration of approximately USD 166.4 million. Assertio is a Nasdaq-listed pharmaceutical company (ASRT) focused on specialty and oncology supportive-care therapies, with its key product ROLVEDON® approved by USFDA for preventing febrile neutropenia in cancer patients. The transaction is structured as a tender offer followed by a merger, with 100% shareholding targeted. Upon completion, Assertio will be delisted from Nasdaq. The deal is expected to close in financial year 2026-27, subject to customary closing conditions and regulatory approvals. This acquisition gives Zydus immediate access to Assertio's 170+ community oncology accounts and commercial infrastructure.
This acquisition strengthens Zydus's specialty oncology presence in the U.S. market by providing an immediate commercial platform and an approved biotech product. For shareholders, this represents Zydus's strategic expansion into specialty pharmaceuticals with a ready-made U.S. sales infrastructure.